Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials

Summary Concerns have been raised regarding an increased risk of major adverse cardiovascular events (MACEs) (myocardial infarction, cerebrovascular accident or cardiovascular death) in patients treated with anti‐interleukin (IL)‐12/23 agents for moderate‐to‐severe psoriasis. We aimed to examine the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2017-04, Vol.176 (4), p.890-901
Hauptverfasser:	Rungapiromnan, W., Yiu, Z.Z.N., Warren, R.B., Griffiths, C.E.M., Ashcroft, D.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - adverse effects Biological Factors - adverse effects Cardiovascular diseases Cardiovascular Diseases - chemically induced Cerebrovascular system Clinical trials Death, Sudden, Cardiac - etiology Etanercept Female Humans Infliximab Interleukin-12 - antagonists & inhibitors Interleukin-17 - antagonists & inhibitors Interleukin-23 - antagonists & inhibitors Licenses Male Meta-analysis Middle Aged Monoclonal antibodies Myocardial infarction Myocardial Infarction - chemically induced Psoriasis Psoriasis - drug therapy Randomized Controlled Trials as Topic Reviews Risk Factors Statistical analysis Stroke Stroke - chemically induced Systematic Review Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-α Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!